Kempin, S., Sun, Z., Kay, N. E., Paietta, E. M., Mazza, J. J., Ketterling, R. P., . . . Tallman, M. S. (2019). Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903). Acta Haematol.
Citação norma ChicagoKempin, Sanford, et al. "Pentostatin, Cyclophosphamide and Rituximab Followed By Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)." Acta Haematol 2019.
MLA CitationKempin, Sanford, et al. "Pentostatin, Cyclophosphamide and Rituximab Followed By Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)." Acta Haematol 2019.